Home Purpose Portfolio People Perspectives

Perspectives

Conversations

News

Insights

Analysis

Conversations

News

Insights

Analysis

Fierce Biotech: Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger

Fierce Biotech: Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger

VentureBeat: Emergence AI’s CRAFT arrives to make it easy for enterprises to automate their entire data pipeline

VentureBeat: Emergence AI’s CRAFT arrives to make it easy for enterprises to automate their entire data pipeline

Fierce Biotech: Gilgamesh links psychedelic to 94% remission rate in midphase depression trial

Fierce Biotech: Gilgamesh links psychedelic to 94% remission rate in midphase depression trial

Entrepreneur: AI That Creates AI: The Next Big Innovation

Entrepreneur: AI That Creates AI: The Next Big Innovation

VentureBeat: Emergence AI’s new system automatically creates AI agents rapidly in realtime based on the work at hand

VentureBeat: Emergence AI’s new system automatically creates AI agents rapidly in realtime based on the work at hand

A Noetic new year

A Noetic new year

Seeking truth in healing

Seeking truth in healing

Fierce Biotech: 2024 Fierce 15 [Gilgamesh]

Fierce Biotech: 2024 Fierce 15 [Gilgamesh]

TechCrunch: Emergence thinks it can crack the AI agent code

TechCrunch: Emergence thinks it can crack the AI agent code

Fierce Biotech: AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh

Fierce Biotech: AbbVie inks $2B-plus next-gen neuro deal with Gilgamesh

Business Insider: Beckley Psytech's investors want to put more money into the psychedelics company at a $200 million valuation

Business Insider: Beckley Psytech's investors want to put more money into the psychedelics company at a $200 million valuation

TechCrunch: 11 investors predict a colorful, if difficult, future for psychedelic startups

TechCrunch: 11 investors predict a colorful, if difficult, future for psychedelic startups

Business Insider: Meet the top 14 VCs who've bet the most cash on turning psychedelics into medical treatments

Business Insider: Meet the top 14 VCs who've bet the most cash on turning psychedelics into medical treatments

Why invest in neuroscience venture capital now?

Why invest in neuroscience venture capital now?

Dr. Rick Strassman | Becoming the 'godfather' of DMT

Dr. Rick Strassman | Becoming the 'godfather' of DMT

TechCrunch: Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride

TechCrunch: Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride

Dr. Rachel Yehuda | Challenges & opportunities in psychedelic therapy

Dr. Rachel Yehuda | Challenges & opportunities in psychedelic therapy

Dr. Richard Louis Miller | On virtue, incentives & heresy in psychedelic medicine

Dr. Richard Louis Miller | On virtue, incentives & heresy in psychedelic medicine

Ultra-athlete Charlie Engle | Facing demons & overcoming impossible odds

Ultra-athlete Charlie Engle | Facing demons & overcoming impossible odds

Dr. Anthony Bossis | Mystical experiences & psilocybin for palliative care

Dr. Anthony Bossis | Mystical experiences & psilocybin for palliative care

Luis Eduardo Luna | On animism & the philosophy of psychedelics

Luis Eduardo Luna | On animism & the philosophy of psychedelics

LA Times: Ayahuasca changed this hedge funder’s life. Now he’s bankrolling a psychedelic boom‍

LA Times: Ayahuasca changed this hedge funder’s life. Now he’s bankrolling a psychedelic boom‍

Dr. Michael Winkelman | Plant medicine & human evolution - Back to the future?

Dr. Michael Winkelman | Plant medicine & human evolution - Back to the future?

Director Louie Schwartzberg | Psychedelics, consciousness & the visual arts

Director Louie Schwartzberg | Psychedelics, consciousness & the visual arts

Stan & Brigitte Grof | On cosmic wisdom & psychedelic-assisted therapy

Stan & Brigitte Grof | On cosmic wisdom & psychedelic-assisted therapy

Rick Doblin | MAPS & global psychedelic research

Rick Doblin | MAPS & global psychedelic research

Business Insider: Experts share how a brewing fight could shape the future of the $100 billion psychedelics industry

Business Insider: Experts share how a brewing fight could shape the future of the $100 billion psychedelics industry

Dr. Richard Louis Miller | All about psychedelic-assisted therapy

Dr. Richard Louis Miller | All about psychedelic-assisted therapy

Dr. Rachel Yehuda | On PTSD & the promise of MDMA-assisted therapy

Dr. Rachel Yehuda | On PTSD & the promise of MDMA-assisted therapy

The Indigenous roots of psychedelic medicine | Pt. 2, Appropriation & reciprocity

The Indigenous roots of psychedelic medicine | Pt. 2, Appropriation & reciprocity

Brian C. Muraresku & Dr. Andrew Koh | Exploring the role of psychedelics in early religion

Brian C. Muraresku & Dr. Andrew Koh | Exploring the role of psychedelics in early religion

The Indigenous roots of psychedelic medicine | Pt. 1, Historical use

The Indigenous roots of psychedelic medicine | Pt. 1, Historical use

Investor Portal

/

/

/

Join us for the latest updates.

Join us for the latest updates.

Thank you for joining our community

©

<year>

Noetic

Design by Altalogy